Biocon Biologics UK PLC

Quick facts

Marketed products

• Herceptin Hylecta® · Oncology
  Herceptin Hylecta is a subcutaneous formulation of trastuzumab that binds to HER2 receptors on cancer cells to block growth signaling and trigger immune-mediated cell death.

Phase 1 pipeline

• Bmab1700
• Bmab3000

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Biocon Biologics UK PLC portfolio CI brief
• Biocon Biologics UK PLC pipeline updates RSS